Prevalence of Liver Fibrosis and Progression of Liver Fibrosis

Helen Kovari-Kramer

Status

Unknown

Conditions

HIV Infection and Chronic Alanine Aminotransferase Elevation

Treatments

Other: Fibroscan

Study type

Observational

Funder types

Other

NETWORK

Identifiers

NCT01208376

SHCS 625

Details and patient eligibility

About

Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection. Study aim is first to evaluate the prevalence of liver fibrosis and cirrhosis in HIV-infected patients with chronic ALT elevation and no chronic viral hepatitis using non-invasive diagnostic tests and second to find associated factors with significant fibrosis and cirrhosis. In a second longitudinal part we intend to assess fibrosis progression within 1 and 3 years.

Enrollment

195 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria: Case patients:

HIV-1 infection
no hepatitis B and C coinfection
chronic alanine aminotransferase (ALT) elevation after 1.1.2007
signed informed consent
no other common cause of liver disease

Control patients:

HIV-infection
no hepatitis B and C coinfection
no ALT elevation after 1.1.2002, the date when ALT values were regularly collected in the Swiss HIV Cohort Study (SHCS)
no known chronic liver disease

Exclusion criteria: please see inclusion criteria